Literature DB >> 17608762

ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.

Hendrik B Feys1, Maria T Canciani, Flora Peyvandi, Hans Deckmyn, Karen Vanhoorelbeke, Pier M Mannucci.   

Abstract

The plasma metalloprotease ADAMTS13 (A Disintegrin And Metalloprotease with ThromboSpondin type 1 motif 13) cleaves prothrombotic ultralarge multimers of the platelet-adhesive protein von Willebrand factor (ULVWF) into less active multimers that promote haemostasis in injured blood vessels. When the enzyme is dysfunctional or undetectable, circulating ULVWF may cause massive intravascular aggregation of platelets and thrombotic thrombocytopenic purpura. This study compared ADAMTS13 antigen and activity in a large set of plasmas collected from subjects with various conditions of health and disease, most of which were associated with an increased thrombotic tendency. Pathological conditions were liver cirrhosis (n = 90), inflammatory bowel disease (n = 44) and cardiac surgery (n = 30). Healthy conditions were pregnancy (n = 42), oral contraceptive intake (n = 33) and the neonatal state (n = 41). Normal individuals of different ages were taken as controls (n = 132). The antigen assay showed less variability than the collagen binding-based activity assay. Antigen values correlated well with activity in normal individuals, but were discrepant to various degrees in neonates, pregnancies of later maternal age and cardiac surgery. No discrepancies were noted in liver cirrhosis and inflammatory bowel disease, which were both associated with low-plasma levels of ADAMTS13. The parallel measurement of ADAMTS13 activity and antigen provides a new tool for understanding the behaviour of the VWF cleaving protease in health and disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17608762     DOI: 10.1111/j.1365-2141.2007.06688.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  37 in total

1.  [Thrombotic microangiopathy after extracorporeal circulation: important differential diagnosis].

Authors:  T Schmidt; D A Tsakiris; M Grapow; M Siegemund
Journal:  Anaesthesist       Date:  2010-12-25       Impact factor: 1.041

Review 2.  Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

Review 3.  ADAMTS proteins in human disorders.

Authors:  Timothy J Mead; Suneel S Apte
Journal:  Matrix Biol       Date:  2018-06-06       Impact factor: 11.583

Review 4.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

5.  Levels of TAFI, TFPI and ADAMTS-13 in inflammatory bowel disease.

Authors:  Bilgehan Yüzbaşıoğlu; Müge Ustaoğlu; Şule Yüzbaşıoğlu; Ulaş Emre Akbulut; Kamil Özdil
Journal:  Turk J Gastroenterol       Date:  2019-12       Impact factor: 1.852

6.  Expression of ADAMTS13 in Normal and Abnormal Placentae and Its Potential Role in Angiogenesis and Placenta Development.

Authors:  Juan Xiao; Yun Feng; Xueyin Li; Wei Li; Lei Fan; Jing Liu; Xue Zeng; Kaiyue Chen; Xi Chen; Xiaoshui Zhou; X Long Zheng; Suhua Chen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-07-27       Impact factor: 8.311

7.  Role of reduced ADAMTS13 in arterial ischemic stroke: a pediatric cohort study.

Authors:  Moritz Lambers; Neil A Goldenberg; Gili Kenet; Fenella J Kirkham; Daniela Manner; Timothy Bernard; Rolf M Mesters; Ralf Junker; Monika Stoll; Ulrike Nowak-Göttl
Journal:  Ann Neurol       Date:  2012-12-07       Impact factor: 10.422

8.  Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell-mediated gene therapy.

Authors:  Pablo Laje; Dezhi Shang; Wenjing Cao; Masami Niiya; Masayuki Endo; Antoneta Radu; Nicole DeRogatis; Friedrich Scheiflinger; Philip W Zoltick; Alan W Flake; X Long Zheng
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 9.  Pivotal role of ADAMTS13 function in liver diseases.

Authors:  Masahito Uemura; Yoshihiro Fujimura; Saiho Ko; Masanori Matsumoto; Yoshiyuki Nakajima; Hiroshi Fukui
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

10.  Multi-step binding of ADAMTS-13 to von Willebrand factor.

Authors:  H B Feys; P J Anderson; K Vanhoorelbeke; E M Majerus; J E Sadler
Journal:  J Thromb Haemost       Date:  2009-09-18       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.